article thumbnail

Mechanisms and treatment of pulmonary arterial hypertension

Nature Reviews - Cardiology

Nature Reviews Cardiology, Published online: 07 August 2024; doi:10.1038/s41569-024-01064-4 In this Review, Ghofrani and colleagues discuss the mechanisms underlying the development of pulmonary arterial hypertension, provide an overview of approved therapies and describe the predominantly non-vasodilatory drugs that are currently being tested in clinical (..)

Pulmonary 140
article thumbnail

Ultrasound Neuromodulation Shows Promise to Treat Pulmonary Hypertension, Feinstein Institutes Research

DAIC

(Credit: Feinstein Institutes) milla1cf Wed, 05/08/2024 - 10:57 May 8, 2024 — Ultrasound could one day complement or even replace drugs to treat diseases. PAH is caused by constriction and wall thickening of pulmonary arteries that carry blood from the heart to the lungs for oxygenation.

article thumbnail

Hormone replacement therapy may improve pulmonary hypertension and right ventricular function

Medical Xpress - Cardiology

The use of hormone replacement therapy (HRT) may be associated with improved pulmonary hypertension in women, according to research presented at the ATS 2024 International Conference held May 17–22 in San Diego.

article thumbnail

Aria CV Announces First Patient Successfully Implanted with Second-Generation Pulmonary Hypertension System

DAIC

milla1cf Tue, 02/27/2024 - 17:29 February 27, 2024 — Aria CV, Inc , a developer of medical devices treating pulmonary hypertension, today announced the first patient was implanted with the Gen 2 Aria CV Pulmonary Hypertension System as part of the ASPIRE PH clinical trial at Ascension St.

Pulmonary 110
article thumbnail

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

DAIC

Getty Images mtaschetta-millane Wed, 07/10/2024 - 08:51 July 10, 2024 — Reviva Pharmaceuticals Holdings, Inc. , Founder, President, and CEO. Brilaroxazine has demonstrated a favorable clinical safety and tolerability profile in over 800 subjects to date from multiple clinical trials.

Pulmonary 111
article thumbnail

CardioFocus to Present Data Supporting Next Generation Pulsed Field Ablation Systems at Heart Rhythm 2024

DAIC

milla1cf Wed, 05/15/2024 - 19:05 May 15, 2024 — CardioFocus, Inc. , a medical device company dedicated to advancing ablation treatment for cardiac arrythmias, announced its participation at the Heart Rhythm 2024 conference, taking place in person at the Boston Convention & Exhibition Center and virtually, May 16-19, 2024.

article thumbnail

Breakthrough Research Identifies Predictors of Venous Thromboembolism after Pulmonary Resection for Lung Cancer

DAIC

They looked at anonymous results for 57,531 adult patients who underwent pulmonary resection—removal of all or part of a lung—between January 2009 and June 2021. occurrence of postoperative PE in patients undergoing a first-time pulmonary resection for lung cancer. occurrence of postoperative VTE and a 1.3%

Cancer 116